search
Back to results

Effects of Probiotic and Prebiotic Combinations on Premature Infants

Primary Purpose

Premature Infants, Stool Bacterial Composition, Growth

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ProBioPlus
Culturelle
Placebo
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Premature Infants focused on measuring Probiotic, Prebiotic, NEC, Premature infants, commensal flora

Eligibility Criteria

undefined - 7 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria: less than 35 weeks gestation, birth weight 750-2000 grams born in or transferred to University of California Davis Medical Center within first week of life less than eight days of age at the time of enrollment Exclusion Criteria: Severe intestinal or cardiac congenital anomalies

Sites / Locations

  • University of California Davis Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

ProBioPlus

Culturelle

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Weight Gain
Weight at five weeks minus birth weight

Secondary Outcome Measures

Stool Colonization With Bifidobacteria
Using standard culture techniques, we measured how many of the first 11 infants in each arm of the study grew bifidobacteria in their feces after four weeks of treatment.
Stool Short Chain Butyric Acid Content

Full Information

First Posted
January 23, 2006
Last Updated
December 31, 2009
Sponsor
University of California, Davis
search

1. Study Identification

Unique Protocol Identification Number
NCT00282113
Brief Title
Effects of Probiotic and Prebiotic Combinations on Premature Infants
Official Title
Efficacy of a Prebiotic and Probiotic Combination in Preterm Infants
Study Type
Interventional

2. Study Status

Record Verification Date
December 2009
Overall Recruitment Status
Completed
Study Start Date
October 2004 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of California, Davis

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to see how oral preparations containing both probiotics and prebiotics impact the growth, bacterial colonization of the intestines, and fecal short chain fatty acid content in premature infants. Our hypothesis is that short term growth will be improved, the stool will have more healthy bacteria, and the fecal short chain fatty acid content will increase in the babies who receive the probiotic/prebiotic combinations compared to control groups.
Detailed Description
Premature infants are at risk for a devastating infection of the intestines due to the immaturity of their intestines and immune system. Probiotics are bacteria with healthful qualities that are taken by mouth to improve the number of healthy bacteria in the intestines. Probiotics have been shown in several studies outside the U.S. to decrease the risk of serious intestinal infection and in one small study to improve the rate of weight gain in premature infants. Prebiotics are food supplements that stimulate the growth of healthy bacteria and suppress the growth of unhealthy bacteria. Prebiotics have been shown to improve the numbers of healthy bacteria in the stool of premature babies. Our study is designed to compare two over the counter probiotic/prebiotic combinations to each other and to a control group. Infants less than 35 weeks with a birthweight of 750-2000 gm are eligible and must be enrolled in the study within the first week of life. The babies are randomly assigned to either a control group (no probiotic/prebiotic, just a placebo), a group which receives Culturelle (Lactobacillus rhamnosus GG plus fructo-oligosaccharide, ConAgra), or a group which receives ProBioPlus (three strains of Bifidobacteria plus Lactobacillus acidophilus plus fructo-oligosaccharide, UAS Laboratories). The babies receive the study product by mouth twice daily for 28 days or until discharge (whichever comes first). Weekly measurements (weight, length, head size) and stool cultures are performed. Clinical progress is closely monitored and any episodes of infection are recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Infants, Stool Bacterial Composition, Growth
Keywords
Probiotic, Prebiotic, NEC, Premature infants, commensal flora

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ProBioPlus
Arm Type
Active Comparator
Arm Title
Culturelle
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
ProBioPlus
Intervention Description
ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
Intervention Type
Dietary Supplement
Intervention Name(s)
Culturelle
Intervention Description
Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
Primary Outcome Measure Information:
Title
Weight Gain
Description
Weight at five weeks minus birth weight
Time Frame
5 weeks
Secondary Outcome Measure Information:
Title
Stool Colonization With Bifidobacteria
Description
Using standard culture techniques, we measured how many of the first 11 infants in each arm of the study grew bifidobacteria in their feces after four weeks of treatment.
Time Frame
4 weeks
Title
Stool Short Chain Butyric Acid Content
Time Frame
4 weeks

10. Eligibility

Sex
All
Maximum Age & Unit of Time
7 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: less than 35 weeks gestation, birth weight 750-2000 grams born in or transferred to University of California Davis Medical Center within first week of life less than eight days of age at the time of enrollment Exclusion Criteria: Severe intestinal or cardiac congenital anomalies
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael P Sherman, MD
Organizational Affiliation
University of California, Davis
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California Davis Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19179885
Citation
Underwood MA, Salzman NH, Bennett SH, Barman M, Mills DA, Marcobal A, Tancredi DJ, Bevins CL, Sherman MP. A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):216-25. doi: 10.1097/MPG.0b013e31818de195.
Results Reference
result

Learn more about this trial

Effects of Probiotic and Prebiotic Combinations on Premature Infants

We'll reach out to this number within 24 hrs